Moderna Inventory Is Upgraded on Development Alternatives Not Associated to Covid

Rate this post


was rising Monday after an analyst at Jefferies upgraded the inventory citing confidence within the vaccine maker’s progress alternatives that aren’t associated to the Covid-19 vaccine.

Jefferies analyst Michael Yee upgraded shares of Moderna (ticker: MRNA) to Purchase from Maintain and elevated his 12-month worth goal on the inventory to $275 from $170. For Moderna, Yee mentioned he sees a “vital new pipeline story and catalysts forward.”

Source link